34 results on '"Basevi, Vittorio"'
Search Results
2. Still Waiting and Searching for Answers
- Author
-
Maestri, Emilio, Maltoni, Susanna, Basevi, Vittorio, Marata, Annamaria, and Magrini, Nicola
- Published
- 2008
3. Methods to estimate maternal mortality: a global perspective
- Author
-
Donati, Serena, Maraschini, Alice, Buoncristiano, Marta, Asole, Simona, Basevi, Vittorio, Da Frè, Monica, Dardanoni, Gabriella, Di Lallo, Domenico, Dubini, Valeria, Lupi, Camilla, Mondo, Luisa, Pezzella, Marcello, Pizzuti, Renato, Polo, Arianna, Rusciani, Raffaella, Spettoli, Daniela, and Voller, Fabio
- Published
- 2016
- Full Text
- View/download PDF
4. Prenatal education for congenital toxoplasmosis
- Author
-
Di Mario, Simona, Basevi, Vittorio, Gagliotti, Carlo, Spettoli, Daniela, Gori, Gianfranco, DʼAmico, Roberto, and Magrini, Nicola
- Published
- 2016
5. Perinatal outcomes in twin late preterm pregnancies: results from an Italian area-based, prospective cohort study.
- Author
-
Monari, Francesca, Chiossi, Giuseppe, Ballarini, Michela, Menichini, Daniela, Gargano, Giancarlo, Coscia, Alessandra, Baronciani, Dante, Facchinetti, Fabio, for the Late Preterm Emilia Romagna Group, Basevi, Vittorio, Tiziana, Frusca, Battagliarin, Giuseppe, Lenzi, Marinella, Ancora, Gina, and Corvaglia, Luigi
- Subjects
PREMATURE infants ,SCIENTIFIC observation ,MULTIVARIATE analysis ,FISHER exact test ,GESTATIONAL age ,PREGNANCY outcomes ,COMPARATIVE studies ,CHI-squared test ,PREGNANCY complications ,DELIVERY (Obstetrics) ,MULTIPLE pregnancy ,LONGITUDINAL method - Abstract
Background: Multiple gestations represent a considerable proportion of pregnancies delivering in the late preterm (LP) period. Only 30% of LP twins are due to spontaneous preterm labor and 70% are medically indicated; among this literature described that 16–50% of indicated LP twin deliveries are non-evidence based. As non-evidence-based delivery indications account for iatrogenic morbidity that could be prevented, the objective of our observational study is to investigate first neonatal outcomes of LP twin pregnancies according to gestational age at delivery, chorionicity and delivery indication, then non evidence-based delivery indications. Methods: Prospective cohort study among twins infants born between 34 + 0 and 36 + 6 weeks, in Emilia Romagna, Italy, during 2013–2015. The primary outcome was a composite of adverse perinatal outcomes. Results: Among 346 LP twins, 84 (23.4%) were monochorionic and 262 (75.7%) were dichorionic; spontaneous preterm labor accounted for 85 (24.6%) deliveries, preterm prelabor rupture of membranes for 66 (19.1%), evidence based indicated deliveries were 117 (33.8%), while non-evidence-based indications were 78 (22.5%). When compared to spontaneous preterm labor or preterm prelabor rupture of membranes, pregnancies delivered due to maternal and/or fetal indications were associated with higher maternal age (p < 0.01), higher gestational age at delivery (p < 0.01), Caucasian race (p 0.04), ART use (p < 0.01), gestational diabetes (p < 0.01), vaginal bleeding (p < 0.01), antenatal corticosteroids (p < 0.01), diagnosis of fetal growth restriction (FGR) (p < 0.01), and monochorionic (p < 0.01). Two hundred twenty-six pregnancies (65.3%) had at least one fetus experiencing one composite of adverse perinatal outcome. Multivariate analysis confirmed that delivery indication did not affect the composite of adverse perinatal outcomes; the only characteristic that affect the outcome after controlling for confounding was gestational age at delivery (p < 0.01). Moreover, there was at least one adverse neonatal outcome for 94% of babies born at 34 weeks, for 73% of those born at 35 weeks and for 46% of those born at 36 weeks (p < 0.01). Conclusion: Our study suggests that the decision to deliver or not twins in LP period should consider gestational age at delivery as the main determinant infants' prognosis. Delivery indications should be accurately considered, to avoid iatrogenic early birth responsible of preventable complications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Perinatal clinical audit
- Author
-
Baronciani, Dante, primary, Basevi, Vittorio, additional, Patorno, Elisabetta, additional, and Ballini, Luciana, additional
- Published
- 2010
- Full Text
- View/download PDF
7. Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1): S11–S61
- Author
-
Basevi, Vittorio, Di Mario, Simona, Morciano, Cristina, Nonino, Francesco, and Magrini, Nicola
- Published
- 2011
- Full Text
- View/download PDF
8. Obstetriciansʼ and Midwivesʼ Attitudes toward Cesarean Section
- Author
-
Monari, Francesca, Di Mario, Simona, Facchinetti, Fabio, and Basevi, Vittorio
- Published
- 2008
9. TIBOLONE: Still waiting and searching for answers
- Author
-
Maestri, Emilio, Maltoni, Susanna, Basevi, Vittorio, Marata, Annamaria, and Magrini, Nicola
- Published
- 2008
10. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity
- Author
-
Schaap, T, Bloemenkamp, K, Deneux-Tharaux, Cairns, Knight, Megan, Langhoff-Roos, J., Sullivan, Elizabeth, van den Akker, T, Rigouzzo, Agnes, Univ, Comenius, Creanga, Andreea, Koopman, Ankie, Franx, Arie, Nemethova, Bianka, Bateman, Brian, Daelemans, Caroline, Zelop, Carolyn, Medicine, Boston University School, Nagata, Chie, Farquhar, Cindy M., Huisman, Claartje, von Kaisenberg, Constantin, Henruquez, Dacia, Ellwood, David, Moolenaar, David, Kuklina, Elena, Main, Elliott, Stekkinger, Eva, Gollo, Evelina, Goffinet, Francois, Kainer, Franz, Africa, University of Pretoria Kalafong Academic Hospital, Stralen, Giel, Kayem, Gilles, Duvekot, Hans, Franz, Heiko B G, Engjom, Hilde, Beenakkers, Ingrid, Al-Zirqi, Iqbal, Danis, Jakub, Berlac, Foss, UK, Leicester Royal, Parsonage, Will, Zwart, Joost, van Roosmalen, Jos, Klungsor, Kari, Lust, Karin, Vetter, Klaus, Calsteren, Kristel, Roelens, Kristien, Krebs, Lone, Colmorn, Berdiin, Tanaka, Mamoru, Rijken, Marcus, Bonnet, Marie-Pierre, Boer, Marjon, Jokinen, Mervi, Belfort, Michael, Peek, Michael, Gisler, Mika, Foley, Mike, Tikkanen, Minna, Korbel, Miroslav, laubach, Monika, Schuitemaker, Nico, Engel, Nicole, McDonnell, Nolan, Emonts, Patrick, Rozenberg, Patrick, Hillemanns, Peter, Rauskolb, Rudiger, Takeda, Satoru, Donati, Serena, Ferrazzani, Sergio, Saito, Shigeru, Jesudason, Shilpanjali, Satoh, Shoji, Health, Norwegian Institute of, Clark, Steven, Koenen, Steven, Grussner, Susanne, Miyashita, Susumu, Fischer, Thorsten, Todros, Tullia, Mijatovic, Veljia, Basevi, Vittorio, Pollock, Wendy, Callaghan, William, Henrich, Wolfgang, Fujita, Yasuyuki, Matsuda, Yoshio, Garnier, Yves, Zentner, Dominica, other, and, Schaap, T, Bloemenkamp, K, Deneux-Tharaux, Cairns, Knight, Megan, Langhoff-Roos, J., Sullivan, Elizabeth, van den Akker, T, Rigouzzo, Agnes, Univ, Comenius, Creanga, Andreea, Koopman, Ankie, Franx, Arie, Nemethova, Bianka, Bateman, Brian, Daelemans, Caroline, Zelop, Carolyn, Medicine, Boston University School, Nagata, Chie, Farquhar, Cindy M., Huisman, Claartje, von Kaisenberg, Constantin, Henruquez, Dacia, Ellwood, David, Moolenaar, David, Kuklina, Elena, Main, Elliott, Stekkinger, Eva, Gollo, Evelina, Goffinet, Francois, Kainer, Franz, Africa, University of Pretoria Kalafong Academic Hospital, Stralen, Giel, Kayem, Gilles, Duvekot, Hans, Franz, Heiko B G, Engjom, Hilde, Beenakkers, Ingrid, Al-Zirqi, Iqbal, Danis, Jakub, Berlac, Foss, UK, Leicester Royal, Parsonage, Will, Zwart, Joost, van Roosmalen, Jos, Klungsor, Kari, Lust, Karin, Vetter, Klaus, Calsteren, Kristel, Roelens, Kristien, Krebs, Lone, Colmorn, Berdiin, Tanaka, Mamoru, Rijken, Marcus, Bonnet, Marie-Pierre, Boer, Marjon, Jokinen, Mervi, Belfort, Michael, Peek, Michael, Gisler, Mika, Foley, Mike, Tikkanen, Minna, Korbel, Miroslav, laubach, Monika, Schuitemaker, Nico, Engel, Nicole, McDonnell, Nolan, Emonts, Patrick, Rozenberg, Patrick, Hillemanns, Peter, Rauskolb, Rudiger, Takeda, Satoru, Donati, Serena, Ferrazzani, Sergio, Saito, Shigeru, Jesudason, Shilpanjali, Satoh, Shoji, Health, Norwegian Institute of, Clark, Steven, Koenen, Steven, Grussner, Susanne, Miyashita, Susumu, Fischer, Thorsten, Todros, Tullia, Mijatovic, Veljia, Basevi, Vittorio, Pollock, Wendy, Callaghan, William, Henrich, Wolfgang, Fujita, Yasuyuki, Matsuda, Yoshio, Garnier, Yves, Zentner, Dominica, and other, and
- Abstract
Objective: Develop a core outcome set of international consensus definitions for severe maternal morbidities. Design: Electronic Delphi study. Setting: International. Population: Eight expert panels. Methods: All 13 high-income countries represented in the International Network of Obstetric Surveillance Systems (INOSS) nominated five experts per condition of morbidity, who submitted possible definitions. From these suggestions, a steering committee distilled critical components: eclampsia: 23, amniotic fluid embolism: 15, pregnancy-related hysterectomy: 11, severe primary postpartum haemorrhage: 19, uterine rupture: 20, abnormally invasive placentation: 12, spontaneous haemoperitoneum in pregnancy: 16, and cardiac arrest in pregnancy: 10. These components were assessed by the expert panel using a 5-point Likert scale, following which a framework for an encompassing definition was constructed. Possible definitions were evaluated in rounds until a rate of agreement of more than 70% was reached. Expert commentaries were used in each round to improve definitions. Main outcome measures: Definitions with a rate of agreement of more than 70%. Results: The invitation to participate in one or more of eight Delphi processes was accepted by 103 experts from 13 high-income countries. Consensus definitions were developed for all of the conditions. Conclusion: Consensus definitions for eight morbidity conditions were successfully developed using the Delphi process. These should be used in national registrations and international studies, and should be taken up by the Core Outcomes in Women's and Newborn Health initiative. Tweetable abstract: Consensus definitions for eight morbidity conditions were successfully developed using the Delphi process.
- Published
- 2019
11. Maternal suicide in Italy.
- Author
-
Lega, Ilaria, Maraschini, Alice, D'Aloja, Paola, Andreozzi, Silvia, Spettoli, Daniela, Giangreco, Manuela, Vichi, Monica, Loghi, Marzia, Donati, Serena, the Regional maternal mortality working group, Alberico, Salvatore, Antonelli, Antonello, Asole, Simona, Basevi, Vittorio, Borsari, Silvana, Cetin, Irene, Dardanoni, Gabriella, Di Lallo, Domenico, Dubini, Valeria, and Germinario, Cinzia
- Subjects
SUICIDE prevention ,SUICIDE & psychology ,ABORTION ,CHILDBIRTH ,CLINICAL competence ,CONTINUUM of care ,DEATH ,EVALUATION of medical care ,MEDICAL records ,MENTAL illness ,MISCARRIAGE ,MATERNAL mortality ,OBSTETRICS ,PREGNANCY ,PREGNANT women ,PUERPERIUM ,OCCUPATIONAL roles ,PSYCHIATRIC treatment ,DISCHARGE planning ,ATTITUDES of mothers ,DESCRIPTIVE statistics ,ACQUISITION of data methodology - Abstract
Suicide has been identified as one of the most common causes of death among women within 1 year after the end of pregnancy in several high-income countries. The aim of this study was to provide the first estimate of the maternal suicide ratio and a description of the characteristics of women who died by suicide during pregnancy or within 1 year after giving birth, induced abortion or miscarriage (i.e., maternal suicide) in 10 Italian regions, covering 77% of total national births. Maternal suicides were identified through the linkage between regional death registries and hospital discharge databases. Background population data was collected from the national hospital discharge, abortion and mortality databases. The previous psychiatric history of the women who died by maternal suicide was retrieved from the regionally available data sources. A total of 67 cases of maternal suicide were identified, corresponding to a maternal suicide ratio of 2.30 per 100,000 live births in 2006–2012. The suicide rate was 1.18 per 100,000 after giving birth (n = 2,876,193), 2.77 after an induced abortion (n = 650,549) and 2.90 after a miscarriage (n = 379,583). The majority of the women who died by maternal suicide (34/57) had a previous psychiatric history; 15/18 previously diagnosed mental disorders were not registered along with the index pregnancy obstetric records. Suicide is a relevant cause of maternal death in Italy. The continuity of care between primary, mental health and maternity care were found to be critical. Clinicians should be aware of the issue, as they may play an important role in preventing suicide in their patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Women undergoing peripartum hysterectomy due to obstetric hemorrhage: A prospective population-based study.
- Author
-
Maraschini, Alice, Lega, Ilaria, D'Aloja, Paola, Buoncristiano, Marta, Dell'Oro, Stefania, Donati, Serena, Basevi, Vittorio, Dardanoni, Gabriella, Dubini, Valeria, Lupi, Camilla, Martinelli, Pasquale, Mondo, Luisa, Pezzella, Marcello, Puglia, Monia, Rusciani, Raffaella, Schimmenti, Immacolata, Spettoli, Daniela, Voller, Fabio, and Regional Obstetric Surveillance System Working Group
- Subjects
HYSTERECTOMY ,PERIPARTUM cardiomyopathy ,VAGINAL birth after cesarean ,CESAREAN section ,SURGICAL complications ,INTENSIVE care units -- Admission & discharge ,MATERNAL age - Abstract
Introduction: Peripartum hysterectomy is usually undertaken in cases of life-threatening obstetric hemorrhage to prevent the death of the mother. Near-miss events are still under-researched and inappropriate care continues to be a critical issue, even in countries with advanced obstetric surveillance systems. The aim of the present study was to estimate the prevalence, associated factors, management and intraoperative and postoperative complications of peripartum hysterectomy due to obstetric hemorrhage.Material and Methods: A prospective population-based study has been conducted in six Italian regions covering 49% of births in Italy. The study population comprised all women aged 11-59 years undergoing peripartum hysterectomy, from September 2014 to August 2016, due to obstetric hemorrhage within 7 days of delivery. In each maternity unit a trained reference person reported incident cases using electronic data collection forms. The background population comprised all women who delivered in the participating regions during the study period.Results: The overall peripartum hysterectomy prevalence was 1.09 per 1000 maternities, with a large variability among regions, ranging from 0.52 to 1.60. Previous cesarean section (relative risk [RR] 4.97, 95% CI 4.13-5.96), assisted reproductive technology (RR 5.99, 95% CI 4.42-8.11) multiple pregnancy (RR 5.03, 95% CI 3.57-7.09) and maternal age ≥35 years (RR 2.69, 95% CI 2.25-3.21) were the main associated factors for hysterectomy. The most common causes of peripartum hysterectomy were uterine atony (45.1%) and abnormally invasive placentation (40.2%). Intensive care unit admission was reported in 49.9% of cases, 16.8% of women suffered severe morbidity and 5 women died.Conclusions: The rate of peripartum hysterectomy in Italy was three times higher compared with the UK, the Netherlands and the Nordic countries. The wide difference may be associated with women's characteristics, such as age at delivery and previous cesarean section, and with different management options leading to peripartum hysterectomy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Formula feeding increases the risk of antibiotic prescriptions in children up to 2 years: results from a cohort study.
- Author
-
Di Mario, Simona, Gagliotti, Carlo, Donatini, Andrea, Battaglia, Sergio, Buttazzi, Rossella, Balduzzi, Sara, Borsari, Silvana, Basevi, Vittorio, Barbieri, Luca, and the Regional breastfeeding monitoring group, Barella, Cristina, Castellana, Angela, Ghigini, Carla, Maffi, Roberto, Maffini, Ilario, Milani, Anna Maria, Pellizzari, Raffaella, Prazzoli, Marilena, Bussolati, Giovanna, and Dodi, Icilio
- Subjects
INFANT formulas ,MEDICAL prescriptions ,COHORT analysis ,ANIMAL feeding ,BREASTFEEDING - Abstract
Association between the use of infant formula and risks for infants' health is seldom studied in western countries. We set up a historical cohort based on record linkage analysis, combining the data from administrative databases providing individual data. Infants receiving the second dose of pediatric immunization between 2015 and 2017 were included. The main outcome measure was antibiotic prescriptions from enrolment up to 24 months of age, by infant feeding category at enrolment. The extended Cox regression technique was used to account for recurrent events. The infants' cohort included 40,258 5-month-old infants; during the study period, 60,932 antibiotic prescriptions were filled. Compared with infants fully breastfed, children fed with both maternal milk and formula received 106 more antibiotic prescriptions per 1000 children/year, whereas infants receiving formula only had 138 excess prescriptions per 1000 children/year. The association with infant feeding was statistically significant and remained unchanged after adjustment for common confounders (adjusted hazard ratio, HR, for complementary feeding vs full breastfeeding 1.09; 95%CI 1.05 to 1.12; formula only versus full breastfeeding adj. HR 1.12; 95%CI 1.08 to 1.16).Conclusion: In our cohort, we observed a positive association between infant formula use considered a proxy of infections antibiotic prescription rate, considered a proxy of infections. The association followed a gradient.What is Known:• Formula feeding is associated with increased morbidity and mortality even in western countries, but still, it is common.• Information on formula are seldom unbiased; thus, public perception of risks is distorted.What is New:• In a large Italian cohort of infants, formula feeding at 5 months of age results to be associated with an increased rate of antibiotic prescription (considered to be a proxy of infection) up to 24 months of age: the association follows a dose-response relationship.• Record linkage analysis using administrative databases provides useful information at a limited cost. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Corrigendum to “Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV”
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Lopalco, Pier Luigi, additional, Balduzzi, Sara, additional, D’Amico, Roberto, additional, and Magrini, Nicola, additional
- Published
- 2017
- Full Text
- View/download PDF
15. Regular monitoring of breast-feeding rates: feasible and sustainable. The Emilia-Romagna experience
- Author
-
Di Mario, Simona, primary, Borsari, Silvana, additional, Verdini, Eleonora, additional, Battaglia, Sergio, additional, Cisbani, Luca, additional, Sforza, Stefano, additional, Cuoghi, Chiara, additional, and Basevi, Vittorio, additional
- Published
- 2017
- Full Text
- View/download PDF
16. Early or delayed introduction of food? Misunderstanding is in the air
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Panza, Costantino, additional, Conti Nibali, Sergio, additional, and Cattaneo, Adriano, additional
- Published
- 2017
- Full Text
- View/download PDF
17. Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV
- Author
-
Di Mario, Simona, Basevi, Vittorio, Lopalco, Pier Luigi, Balduzzi, Sara, D’Amico, Roberto, and Magrini, Nicola
- Subjects
Article Subject ,female genital diseases and pregnancy complications - Abstract
Background. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and formulation of the adjuvant. Method. A systematic review was conducted to assess the efficacy of the two vaccines against cervical cancer. Outcomes considered were CIN2+, CIN3+, and AIS. Results. Nine reports (38,419 women) were included. At enrolment mean age of women was 20 years, 90% had negative cytology, and 80% were seronegative and/or DNA negative for HPV 16 or 18 (naïve women). In the TVC-naïve, VE against CIN2+ was 58% (95% CI: 35, 72); heterogeneity was detected, VE being 65% (95% CI: 54, 74) for the bivalent and 43% (95% CI: 23, 57) for the quadrivalent. VE against CIN3+ was 78% (95% CI
- Published
- 2015
- Full Text
- View/download PDF
18. Policies on Conflicts of Interest in Health Care Guideline Development: A Cross-Sectional Analysis
- Author
-
Morciano, Cristina, primary, Basevi, Vittorio, additional, Faralli, Carla, additional, Hilton Boon, Michele, additional, Tonon, Sabina, additional, and Taruscio, Domenica, additional
- Published
- 2016
- Full Text
- View/download PDF
19. Short-term and long-term effects of tibolone in postmenopausal women
- Author
-
Formoso, Giulio, primary, Perrone, Enrica, additional, Maltoni, Susanna, additional, Balduzzi, Sara, additional, Wilkinson, Jack, additional, Basevi, Vittorio, additional, Marata, Anna Maria, additional, Magrini, Nicola, additional, D'Amico, Roberto, additional, Bassi, Chiara, additional, and Maestri, Emilio, additional
- Published
- 2016
- Full Text
- View/download PDF
20. Do generic correction algorithms produce reliable estimates?
- Author
-
Donati, Serena, primary, Maraschini, Alice, additional, Lega, Ilaria, additional, Basevi, Vittorio, additional, and Buoncristiano, Marta, additional
- Published
- 2016
- Full Text
- View/download PDF
21. Prenatal education for congenital toxoplasmosis
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Gagliotti, Carlo, additional, Spettoli, Daniela, additional, Gori, Gianfranco, additional, D'Amico, Roberto, additional, and Magrini, Nicola, additional
- Published
- 2015
- Full Text
- View/download PDF
22. Routine perineal shaving on admission in labour
- Author
-
Basevi, Vittorio, primary and Lavender, Tina, additional
- Published
- 2014
- Full Text
- View/download PDF
23. Prenatal education for congenital toxoplasmosis
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Gagliotti, Carlo, additional, Spettoli, Daniela, additional, Gori, Gianfranco, additional, D'Amico, Roberto, additional, and Magrini, Nicola, additional
- Published
- 2013
- Full Text
- View/download PDF
24. Short and long term effects of tibolone in postmenopausal women
- Author
-
Formoso, Giulio, primary, Perrone, Enrica, additional, Maltoni, Susanna, additional, Balduzzi, Sara, additional, D'Amico, Roberto, additional, Bassi, Chiara, additional, Basevi, Vittorio, additional, Marata, Anna Maria, additional, Magrini, Nicola, additional, and Maestri, Emilio, additional
- Published
- 2012
- Full Text
- View/download PDF
25. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Borsari, Silvana, additional, Balduzzi, Sara, additional, and Magrini, Nicola, additional
- Published
- 2012
- Full Text
- View/download PDF
26. Tibolone for menopausal symptoms
- Author
-
Maltoni, Susanna, primary, Basevi, Vittorio, additional, Marata, Anna Maria, additional, Bassi, Chiara, additional, D'Amico, Roberto, additional, and Maestri, Emilio, additional
- Published
- 2010
- Full Text
- View/download PDF
27. Evidence-Based Medicine ed elaborazione di raccomandazioni e linee guida. Approcci metodologici e criticitÀ attuali
- Author
-
Basevi, Vittorio, primary, Baronciani, Dante, additional, Perrone, Enica, additional, and Magrini, Nicola, additional
- Published
- 2010
- Full Text
- View/download PDF
28. Prenatal education for congenital toxoplasmosis
- Author
-
Di Mario, Simona, primary, Basevi, Vittorio, additional, Gagliotti, Carlo, additional, Spettoli, Daniela, additional, Gori, Gianfranco, additional, D'Amico, Roberto, additional, and Magrini, Nicola, additional
- Published
- 2009
- Full Text
- View/download PDF
29. Routine perineal shaving on admission in labour
- Author
-
Basevi, Vittorio, primary and Lavender, Tina, additional
- Published
- 2000
- Full Text
- View/download PDF
30. Baby-Friendly Hospitals and Cesarean Section Rate: A Survey of Italian Hospitals
- Author
-
Di Mario, Simona, Cattaneo, Adriano, Gagliotti, Carlo, Voci, Claudio, and Basevi, Vittorio
- Abstract
AbstractBackground:The Baby-Friendly Hospital Initiative aims at protecting, promoting, and supporting breastfeeding. Cesarean section is known to represent an obstacle to breastfeeding. In this observational study we compared Baby-Friendly and non–Baby-Friendly hospitals (BFHs and non-BFHs, respectively) in terms of cesarean section rate.Materials and Methods:Italian BFHs were compared with non-BFHs located in the same regions. Data used for analysis were type of hospital, annual deliveries, annual cesarean section deliveries, region of location, and BFH status. The primary outcome was a cesarean section rate below a threshold specific for the identified regions; because of skewed distribution, the median rate was chosen. Descriptive and comparative univariate and multivariate analyses were carried out.Results:In 2009, in Italy, there were 20 BFHs located in eight regions. Compared with the 207 non-BFHs with more than 200 annual deliveries located in the same regions, BFHs had a cesarean section rate below the median of the eight regions (30.4%; interquartile range 14.6%), even after adjustment for confounders (adjusted odds ratio, 12.71; 95% confidence interval, 1.84, 87.72). In addition, being a public hospital, performing a higher number of deliveries, and being located in specific regions also predicted a cesarean section rate below the median. Overall, the regions with at least one BFH showed a lower cesarean section rate, compared with regions without BFHs.Discussion:In Italy there are few BFHs, but regions with at least one BFH show a cesarean section rate below the national median. Several factors impact on the cesarean section rate, causing huge variation among regions. Nevertheless, within the same region, BFHs have a lower cesarean section rate compared with non-BFHs.
- Published
- 2013
- Full Text
- View/download PDF
31. In response to "missed opportunities and potentially misleading results in maternal mortality study".
- Author
-
Donati, Serena, Maraschini, Alice, Lega, Ilaria, D'Aloja, Paola, Buoncristiano, Marta, Manno, Valerio, Alberico, Salvatore, Antonelli, Antonello, Asole, Simona, Basevi, Vittorio, Cetin, Irene, Chiodini, Paolo, Dardanoni, Gabriella, Di Lallo, Domenico, Dubini, Valeria, Germinario, Cinzia, Giangreco, Manuela, Gnaulati, Lisa, Loverro, Giuseppe, and Lupi, Camilla
- Subjects
PREGNANT women ,MATERNAL mortality ,REPRODUCTIVE health - Published
- 2019
- Full Text
- View/download PDF
32. Screening of Chagas disease in pregnant women—Recommendation by the Italian National Institute of Health, 2023.
- Author
-
Ornaghi, Sara, Corsi Decenti, Edoardo, Zammarchi, Lorenzo, Bartoloni, Alessandro, Angheben, Andrea, Nava, Chiara, Tommasella, Margherita, Carletti, Valerio, Colciago, Elisabetta, Dell'Oro, Stefania, Farsetti, Daniele, Finale, Enrico, Fumagalli, Simona, Giovinale, Silvia, Iannuzzi, Laura, Maellaro, Filomena, Maggiora, Elena, Pometti, Francesca, Sampaolo, Letizia, and Basevi, Vittorio
- Subjects
- *
PREGNANCY complications , *CHAGAS' disease , *MEDICAL screening , *LATIN Americans - Abstract
The article discusses the recommendation by the Italian National Institute of Health for the screening of Chagas disease in pregnant women. Chagas disease is a vector-borne infection caused by the protozoan Trypanosoma cruzi and affects approximately 8 million people worldwide. The disease can be transmitted through various means, including vertical transmission from mother to child during pregnancy. The article emphasizes the importance of screening pregnant women at risk for Chagas disease and providing appropriate counseling and treatment. The World Health Organization has also included the elimination of Chagas disease as an objective in its new roadmap. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
33. Short-term and long-term effects of tibolone in postmenopausal women
- Author
-
Anna Maria Marata, Vittorio Basevi, Chiara Bassi, Roberto D'Amico, Sara Balduzzi, Susanna Maltoni, Emilio Maestri, Giulio Formoso, Nicola Magrini, Enrica Perrone, Jack Wilkinson, Formoso, Giulio, Perrone, Enrica, Maltoni, Susanna, Balduzzi, Sara, Wilkinson, Jack, Basevi, Vittorio, Marata, Anna Maria, Magrini, Nicola, D'Amico, Roberto, Bassi, Chiara, and Maestri, Emilio
- Subjects
Tibolone ,Aged ,Breast Neoplasms ,Dyspareunia ,Estrogen Receptor Modulators ,Estrogen Replacement Therapy ,Female ,Hot Flashes ,Humans ,Middle Aged ,Neoplasm Recurrence, Local ,Norpregnenes ,Postmenopause ,Randomized Controlled Trials as Topic ,Stroke ,Sweating ,Uterine Hemorrhage ,Medicine (all) ,Pharmacology (medical) ,law.invention ,0302 clinical medicine ,Estrogen Receptor Modulator ,Randomized controlled trial ,law ,030212 general & internal medicine ,030219 obstetrics & reproductive medicine ,Local ,Meta-analysis ,medicine.symptom ,Breast Neoplasm ,medicine.drug ,Human ,Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,Hot Flashe ,Placebo ,03 medical and health sciences ,Breast cancer ,Internal medicine ,medicine ,Vaginal bleeding ,Adverse effect ,Gynecology ,Norpregnene ,business.industry ,Odds ratio ,medicine.disease ,Neoplasm Recurrence ,business - Abstract
Background Tibolone is a synthetic steroid used for the treatment of menopausal symptoms, on the basis of short-term data suggesting its efficacy. We considered the balance between the benefits and risks of tibolone. Objectives To evaluate the effectiveness and safety of tibolone for treatment of postmenopausal and perimenopausal women. Search methods In October 2015, we searched the Gynaecology and Fertility Group (CGF) Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and PsycINFO (from inception), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and clinicaltrials.gov. We checked the reference lists in articles retrieved. Selection criteria We included randomised controlled trials (RCTs) comparing tibolone versus placebo, oestrogens and/or combined hormone therapy (HT) in postmenopausal and perimenopausal women. Data collection and analysis We used standard methodological procedures of The Cochrane Collaboration. Primary outcomes were vasomotor symptoms, unscheduled vaginal bleeding and long-term adverse events. We evaluated safety outcomes and bleeding in studies including women either with or without menopausal symptoms. Main results We included 46 RCTs (19,976 women). Most RCTs evaluated tibolone for treating menopausal vasomotor symptoms. Some had other objectives, such as assessment of bleeding patterns, endometrial safety, bone health, sexuality and safety in women with a history of breast cancer. Two included women with uterine leiomyoma or lupus erythematosus. Tibolone versus placebo Vasomotor symptoms Tibolone was more effective than placebo (standard mean difference (SMD) -0.99, 95% confidence interval (CI) -1.10 to -0.89; seven RCTs; 1657 women; moderate-quality evidence), but removing trials at high risk of attrition bias attenuated this effect (SMD -0.61, 95% CI -0.73 to -0.49; odds ratio (OR) 0.33, 85% CI 0.27 to 0.41). This suggests that if 67% of women taking placebo experience vasomotor symptoms, between 35% and 45% of women taking tibolone will do so. Unscheduled bleeding Tibolone was associated with greater likelihood of bleeding (OR 2.79, 95% CI 2.10 to 3.70; nine RCTs; 7814 women; I2 = 43%; moderate-quality evidence). This suggests that if 18% of women taking placebo experience unscheduled bleeding, between 31% and 44% of women taking tibolone will do so. Long-term adverse events Most of the studies reporting these outcomes provided follow-up of two to three years (range three months to three years). Breast cancer We found no evidence of differences between groups among women with no history of breast cancer (OR 0.52, 95% CI 0.21 to 1.25; four RCTs; 5500 women; I2= 17%; very low-quality evidence). Among women with a history of breast cancer, tibolone was associated with increased risk (OR 1.5, 95% CI 1.21 to 1.85; two RCTs; 3165 women; moderate-quality evidence). Cerebrovascular events We found no conclusive evidence of differences between groups in cerebrovascular events (OR 1.74, 95% CI 0.99 to 3.04; four RCTs; 7930 women; I2 = 0%; very low-quality evidence). We obtained most data from a single RCT (n = 4506) of osteoporotic women aged 60 to 85 years, which was stopped prematurely for increased risk of stroke. Other outcomes Evidence on other outcomes was of low or very low quality, with no clear evidence of any differences between the groups. Effect estimates were as follows: • Endometrial cancer: OR 2.04, 95% CI 0.79 to 5.24; nine RCTs; 8504 women; I2 = 0%. • Cardiovascular events: OR 1.38, 95% CI 0.84 to 2.27; four RCTs; 8401 women; I2 = 0%. • Venous thromboembolic events: OR 0.85, 95% CI 0.37 to 1.97; 9176 women; I2 = 0%. • Mortality from any cause: OR 1.06, 95% CI 0.79 to 1.41; four RCTs; 8242 women; I2 = 0%. Tibolone versus combined HT Vasomotor symptoms Combined HT was more effective than tibolone (SMD 0.17, 95% CI 0.06 to 0.28; OR 1.36, 95% CI 1.11 to 1.66; nine studies; 1336 women; moderate-quality evidence). This result was robust to a sensitivity analysis that excluded trials with high risk of attrition bias, suggesting a slightly greater disadvantage of tibolone (SMD 0.25, 95% CI 0.09 to 0.41; OR 1.57, 95% CI 1.18 to 2.10). This suggests that if 7% of women taking combined HT experience vasomotor symptoms, between 8% and 14% of women taking tibolone will do so. Unscheduled bleeding Tibolone was associated with a lower rate of bleeding (OR 0.32, 95% CI 0.24 to 0.41; 16 RCTs; 6438 women; I2 = 72%; moderate-quality evidence). This suggests that if 47% of women taking combined HT experience unscheduled bleeding, between 18% and 27% of women taking tibolone will do so. Long-term adverse events Most studies reporting these outcomes provided follow-up of two to three years (range three months to three years). Evidence was of very low quality, with no clear evidence of any differences between the groups. Effect estimates were as follows: • Endometrial cancer: OR 1.47, 95% CI 0.23 to 9.33; five RCTs; 3689 women; I2 = 0%. • Breast cancer: OR 1.69, 95% CI 0.78 to 3.67; five RCTs; 4835 women; I2 = 0%. • Venous thromboembolic events: OR 0.44, 95% CI 0.09 to 2.14; four RCTs; 4529 women; I2 = 0%. • Cardiovascular events: OR 0.63, 95% CI 0.24 to 1.66; two RCTs; 3794 women; I2 = 0%. • Cerebrovascular events: OR 0.76, 95% CI 0.16 to 3.66; four RCTs; 4562 women; I2 = 0%. • Mortality from any cause: only one event reported (two RCTs; 970 women). Authors' conclusions Moderate-quality evidence suggests that tibolone is more effective than placebo but less effective than HT in reducing menopausal vasomotor symptoms, and that tibolone is associated with a higher rate of unscheduled bleeding than placebo but with a lower rate than HT. Compared with placebo, tibolone increases recurrent breast cancer rates in women with a history of breast cancer, and may increase stroke rates in women over 60 years of age. No evidence indicates that tibolone increases the risk of other long-term adverse events, or that it differs from HT with respect to long-term safety. Much of the evidence was of low or very low quality. Limitations included high risk of bias and imprecision. Most studies were financed by drug manufacturers or failed to disclose their funding source.
- Published
- 2016
34. Still waiting and searching for answers.
- Author
-
Maestri E, Maltoni S, Basevi V, Marata A, and Magrini N
- Subjects
- Female, Humans, Randomized Controlled Trials as Topic, Estrogen Receptor Modulators therapeutic use, Fractures, Bone prevention & control, Norpregnenes therapeutic use, Osteoporosis, Postmenopausal complications
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.